

Consolidated Financial Results for the First Quarter of FY2017

Consolidated Subsidiaries: 2

ASKA Pharma Medical Co., Ltd. / ASKA Animal Health Co., Ltd.

	FY2016 Q1		FY2017 Q1		YoY
	Apr. 2016-Jun. 2016		Apr. 2017-Jun. 2017		
	Millions of Yen	Ratio	Millions of Yen	Ratio	
Net Sales	11,987	100.0%	12,813	100.0%	106.9%
Cost of Sales	7,503	62.6%	7,751	60.5%	103.3%
Gross Profit	4,484	37.4%	5,062	39.5%	112.9%
Selling, General and Administrative Expenses	4,019	33.5%	3,986	31.1%	99.2%
Operating Income	462	3.9%	1,077	8.4%	232.8%
Profit Attributable to Owners of Parent	526	4.4%	1,043	8.1%	198.3%

Forecast of Consolidated Financial Results for the FY2017

	FY2017 Q2 Forecast		FY2017 Forecast	
	Apr. 2017-Sep. 2017		Apr. 2017-Mar. 2018	
	Millions of Yen	Ratio	Millions of Yen	Ratio
Net Sales	25,000	100.0%	50,000	100.0%
Operating Income	1,400	5.6%	2,000	4.0%
Profit Attributable to Owners of Parent	1,300	5.2%	1,800	3.6%

Sales of Main Products

(Billions of yen)

Therapeutic Category	Products	FY2016 Q1 Actual	FY2017 Q1 Actual	FY2017 Forecast
Antihypertensive agent	CANDESARTAN*	2.97	3.56	13.64
Thyroid hormone	THYRADIN	1.38	1.31	5.50
Hyperlipidemic agent	LIPDIL	0.46	0.46	4.32
LH-RH derivative	LEUPRORELIN	0.89	0.99	3.95
Prostate cancer therapeutic agent	BICALUTAMIDE	0.52	0.45	1.77
Antihypertensive agent	AMLODIPINE	0.43	0.44	1.66
Emergency contraceptive	NORLEVO	0.31	0.32	1.11
Antithyroid agent	MERCAZOLE	0.31	0.28	1.11
Proton pump inhibitor	RABEPRAZOLE	0.25	0.24	0.95
Oral contraceptives	ANGE	0.25	0.23	0.91
Poorly absorbable antimicrobial agent	RIFXIMA	-	0.15	1.40

*Including CANDESARTAN formulation's sales